Osimertinib for stage III lung cancer patients who can't have chemo
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a targeted therapy pill (osimertinib) combined with radiation for people with a specific type of stage III lung cancer (EGFR mutation-positive) who cannot receive chemotherapy. The goal is to see if this treatment can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have stage III non-small cell lung cancer that cannot be removed by surgery.
- Your cancer has an EGFR mutation (either exon 19 deletion or L858R).
- You are not a candidate for chemotherapy or you have refused it.
- You are able and willing to receive radiation therapy.
- You have at least one tumor that can be measured on a CT or MRI scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies osimertinib, a targeted medicine, after surgery to help stop lung cancer from growing or spreading. It’s for people with an early lung cancer that has EGFR mutations and leftover “ground-glass” lung spots in another area.
This Phase 1 study tests the combination of osimertinib (a targeted lung cancer pill) with an antibody called carotuximab to treat advanced EGFR-mutated non-small cell lung cancer. It aims to see whether adding the antibody can help when the cancer has grown despite prior EGFR-targeted therapy.
This trial tests osimertinib (a targeted pill) given after surgery to help prevent early-stage lung cancer from coming back. It’s for people with fully removed, high-risk stage I non-small cell lung cancer that has specific EGFR gene changes.
This trial tests a new combination of the drug osimertinib with chemotherapy for people whose lung cancer has returned after they took osimertinib alone following surgery. It aims to see if this combined approach helps control the cancer better.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
This study tests whether a targeted therapy pill called osimertinib can help people whose lung cancer has returned after they already received targeted therapy following surgery. The goal is to see if this treatment can control the cancer and improve outcomes.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.